CANDIAC, QC, June 4, 2013 /CNW Telbec/ - Uman Pharma is pleased to
announce that it has successfully passed its inspection by the United
States Food and Drug Administration (FDA). The agency has thus
communicated to Uman Pharma that the positive results of its
establishment inspection of the facility clears the way for sale of
products manufactured at the Canadian facility in the United States.
"The FDA is arguably one of the most stringent regulatory agencies. This
positive news will allow Uman to operate in some of the most
restrictive regulatory environments. It will provide Uman Pharma with
an important commercial opportunity and a strategic positioning since
it is one of the few cytotoxic facilities in North America that can
manufacture products for the Canadian, American and European markets."
said Sylvain Duvernay, Uman Pharma's President and CEO.
Uman Pharma is physically located in a hub of the pharmaceutical
industry and now has strategic access to the largest regulated markets.
In addition to this US approval, Canada benefits from a mutual
recognition accord with the European Medicines Agency (EMA) where Uman
Pharma has launched its Methotrexate pre-filled syringes in Germany and
CFR Pharmaceuticals, Uman Pharma's majority shareholder, and an
important player in the rapidly growing South American markets, is
pleased of the outcome of this inspection, the result of a continuous
effort carried by Uman and CFR since the year 2012.
About Uman Pharma
Uman Pharma is a global pharmaceutical company based in Candiac, on the
South Shore of Montreal, Canada. Its strengths lie in the development
and manufacturing of cytotoxic and high potent sterile injectables for
the oncology market. Uman's portfolio of products includes complex and
generic formulations, backed by an experienced and professional team
and GMP manufacturing facilities (11,700m2).
Please visit www.umanpharma.com for more information.
About CFR Pharmaceuticals
CFR Pharmaceuticals S.A. is a leading Latin American pharmaceutical
company with operations in 15 countries in Latin America (mainly Chile,
Peru, Argentina and Colombia), and other emerging markets. Its business
model is focused on the development, manufacture and commercialization
of off-patent and locally unpatented branded specialty pharmaceutical
products. The company manages its operations along several business
Please visit www.cfr-corp.com for more information.
SOURCE: UMAN PHARMA INC.
For further information: